EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital

Sofia Maraki, Viktoria Eirini Mavromanolaki, Dimitra Stafylaki, Evangelia Iliaki-Giannakoudaki, Anna Kasimati

Medical Principles and Practice · 2024 · 33 (4) · 392-398

DOI: 10.1159/000538414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Principles and Practice, online erschienen am 20.03.2024. Verfasst von Sofia Maraki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Greece, sofiamaraki@yahoo.gr. Hauptthemen laut MEDLINE: Clostridioides difficile, Teicoplanin, Anti-Bacterial Agents, Clostridium Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Clostridioides difficile is a major cause of healthcare-associated diarrhea worldwide. For years, metronidazole and vancomycin were considered the standard treatment for C. difficile infection. However, they are increasingly being associated with treatment failure and recurrence. In this study, we investigated the in vitro activity of dalbavancin and fourteen other antimicrobials against 155 toxigenic C. difficile isolates originating from patients with C. difficile-associated diarrhea. Materials and Methods: Antimicrobial susceptibility was evaluated by the MIC Test Strip, and the results were interpreted using both the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints.

Results

C. difficile isolates were fully susceptible to metronidazole, vancomycin, amoxicillin/clavulanate, piperacillin/tazobactam, and tigecycline. All isolates were dalbavancin susceptible by the CLSI breakpoint (≤0.25 μg/mL) compared with 97.4% susceptibility by the EUCAST breakpoint (≤0.125 μg/mL). Dalbavancin demonstrated significantly lower MIC50 and MIC90 values compared to vancomycin (0.047 vs. 0.38 and 0.125 vs. 0.5, respectively, p < 0.001). Resistance rates to penicillin, ampicillin, cefoxitin, imipenem, meropenem, clindamycin, moxifloxacin, chloramphenicol, and tetracycline were 20%, 14.2%, 100%, 75.5%, 0.6%, 51%, 36.1%, 3.2%, and 14.8%, respectively. Multidrug-resistant phenotypes were detected among 41.3% of the isolates.

Conclusion

Dalbavancin exhibited potent activity against the isolates tested. As C. difficile is an important healthcare-associated pathogen, continued surveillance is required to monitor for development of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileTeicoplaninAnti-Bacterial AgentsClostridium InfectionsAnti-Infective AgentsHumansMicrobial Sensitivity TestsTertiary Care CentersGreeceDiarrheaVancomycin

Stichwörter der Autor:innen

Clostridioides difficileAntimicrobial resistanceDalbavancinMetronidazoleVancomycin

Substanzen

TeicoplanindalbavancinAnti-Bacterial AgentsAnti-Infective AgentsVancomycin

Autor:innen und Institutionen

  • Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Greece, sofiamaraki@yahoo.gr.
  • School of Medicine, University of Crete, Heraklion, Greece.
  • Department of Clinical Microbiology and Microbial Pathogenesis, University Hospital of Heraklion, Heraklion, Greece.

Zitieren

APA

Maraki, S., Mavromanolaki, V. E., Stafylaki, D., Iliaki-Giannakoudaki, E., & Kasimati, A. (2024). In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital. Medical Principles and Practice, 33(4), 392-398. https://doi.org/10.1159/000538414

Vancouver

Maraki S, Mavromanolaki VE, Stafylaki D, Iliaki-Giannakoudaki E, Kasimati A. In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital. Medical Principles and Practice. 2024;33(4):392-398. doi:10.1159/000538414

BibTeX
@article{Maraki2024,
  author = {Maraki, Sofia and Mavromanolaki, Viktoria Eirini and Stafylaki, Dimitra and Iliaki-Giannakoudaki, Evangelia and Kasimati, Anna},
  title = {In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital},
  journal = {Medical Principles and Practice},
  year = {2024},
  volume = {33},
  number = {4},
  pages = {392--398},
  doi = {10.1159/000538414}
}
Kostenlos starten →